High-performance affinity chromatography and the analysis of drug interactions with modified proteins

Binding of gliclazide with glycated human serum albumin

Ryan Matsuda, Jeanethe Anguizola, K. S. Joseph, David S Hage

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

This study used high-performance affinity chromatography (HPAC) to examine the binding of gliclazide (i.e., a sulfonylurea drug used to treat diabetes) with the protein human serum albumin (HSA) at various stages of modification due to glycation. Frontal analysis conducted with small HPAC columns was first used to estimate the number of binding sites and association equilibrium constants (K a ) for gliclazide with normal HSA and glycated HSA. Both normal and glycated HSA interacted with gliclazide according to a two-site model, with a class of high-affinity sites (average K a , 7.1-10 × 10 4 M -1 ) and a group of lower-affinity sites (average K a , 5.7-8.9 × 10 3 M -1 ) at pH 7.4 and 37 °C. Competition experiments indicated that Sudlow sites I and II of HSA were both involved in these interactions, with the K a values for gliclazide at these sites being 1.9 × 10 4 and 6.0 × 10 4 M -1 , respectively, for normal HSA. Two samples of glycated HSA had similar affinities to normal HSA for gliclazide at Sudlow site I, but one sample had a 1.9-fold increase in affinity at this site. All three glycated HSA samples differed from normal HSA in their affinity for gliclazide at Sudlow site II. This work illustrated how HPAC can be used to examine both the overall binding of a drug with normal or modified proteins and the site-specific changes that can occur in these interactions as a result of protein modification. [Figure not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)2811-2819
Number of pages9
JournalAnalytical and Bioanalytical Chemistry
Volume401
Issue number9
DOIs
StatePublished - Nov 1 2011

Fingerprint

Gliclazide
Drug interactions
Affinity chromatography
Drug Interactions
Affinity Chromatography
Protein Binding
Serum Albumin
Proteins
Equilibrium constants
Medical problems
Pharmaceutical Preparations
Binding Sites
Association reactions

Keywords

  • Drug-protein interactions
  • Gliclazide
  • Glycation
  • High-performance affinity chromatography
  • Human serum albumin

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

High-performance affinity chromatography and the analysis of drug interactions with modified proteins : Binding of gliclazide with glycated human serum albumin. / Matsuda, Ryan; Anguizola, Jeanethe; Joseph, K. S.; Hage, David S.

In: Analytical and Bioanalytical Chemistry, Vol. 401, No. 9, 01.11.2011, p. 2811-2819.

Research output: Contribution to journalArticle

@article{93d618c699e54408a58702b3f83e2333,
title = "High-performance affinity chromatography and the analysis of drug interactions with modified proteins: Binding of gliclazide with glycated human serum albumin",
abstract = "This study used high-performance affinity chromatography (HPAC) to examine the binding of gliclazide (i.e., a sulfonylurea drug used to treat diabetes) with the protein human serum albumin (HSA) at various stages of modification due to glycation. Frontal analysis conducted with small HPAC columns was first used to estimate the number of binding sites and association equilibrium constants (K a ) for gliclazide with normal HSA and glycated HSA. Both normal and glycated HSA interacted with gliclazide according to a two-site model, with a class of high-affinity sites (average K a , 7.1-10 × 10 4 M -1 ) and a group of lower-affinity sites (average K a , 5.7-8.9 × 10 3 M -1 ) at pH 7.4 and 37 °C. Competition experiments indicated that Sudlow sites I and II of HSA were both involved in these interactions, with the K a values for gliclazide at these sites being 1.9 × 10 4 and 6.0 × 10 4 M -1 , respectively, for normal HSA. Two samples of glycated HSA had similar affinities to normal HSA for gliclazide at Sudlow site I, but one sample had a 1.9-fold increase in affinity at this site. All three glycated HSA samples differed from normal HSA in their affinity for gliclazide at Sudlow site II. This work illustrated how HPAC can be used to examine both the overall binding of a drug with normal or modified proteins and the site-specific changes that can occur in these interactions as a result of protein modification. [Figure not available: see fulltext.]",
keywords = "Drug-protein interactions, Gliclazide, Glycation, High-performance affinity chromatography, Human serum albumin",
author = "Ryan Matsuda and Jeanethe Anguizola and Joseph, {K. S.} and Hage, {David S}",
year = "2011",
month = "11",
day = "1",
doi = "10.1007/s00216-011-5382-8",
language = "English (US)",
volume = "401",
pages = "2811--2819",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "0016-1152",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - High-performance affinity chromatography and the analysis of drug interactions with modified proteins

T2 - Binding of gliclazide with glycated human serum albumin

AU - Matsuda, Ryan

AU - Anguizola, Jeanethe

AU - Joseph, K. S.

AU - Hage, David S

PY - 2011/11/1

Y1 - 2011/11/1

N2 - This study used high-performance affinity chromatography (HPAC) to examine the binding of gliclazide (i.e., a sulfonylurea drug used to treat diabetes) with the protein human serum albumin (HSA) at various stages of modification due to glycation. Frontal analysis conducted with small HPAC columns was first used to estimate the number of binding sites and association equilibrium constants (K a ) for gliclazide with normal HSA and glycated HSA. Both normal and glycated HSA interacted with gliclazide according to a two-site model, with a class of high-affinity sites (average K a , 7.1-10 × 10 4 M -1 ) and a group of lower-affinity sites (average K a , 5.7-8.9 × 10 3 M -1 ) at pH 7.4 and 37 °C. Competition experiments indicated that Sudlow sites I and II of HSA were both involved in these interactions, with the K a values for gliclazide at these sites being 1.9 × 10 4 and 6.0 × 10 4 M -1 , respectively, for normal HSA. Two samples of glycated HSA had similar affinities to normal HSA for gliclazide at Sudlow site I, but one sample had a 1.9-fold increase in affinity at this site. All three glycated HSA samples differed from normal HSA in their affinity for gliclazide at Sudlow site II. This work illustrated how HPAC can be used to examine both the overall binding of a drug with normal or modified proteins and the site-specific changes that can occur in these interactions as a result of protein modification. [Figure not available: see fulltext.]

AB - This study used high-performance affinity chromatography (HPAC) to examine the binding of gliclazide (i.e., a sulfonylurea drug used to treat diabetes) with the protein human serum albumin (HSA) at various stages of modification due to glycation. Frontal analysis conducted with small HPAC columns was first used to estimate the number of binding sites and association equilibrium constants (K a ) for gliclazide with normal HSA and glycated HSA. Both normal and glycated HSA interacted with gliclazide according to a two-site model, with a class of high-affinity sites (average K a , 7.1-10 × 10 4 M -1 ) and a group of lower-affinity sites (average K a , 5.7-8.9 × 10 3 M -1 ) at pH 7.4 and 37 °C. Competition experiments indicated that Sudlow sites I and II of HSA were both involved in these interactions, with the K a values for gliclazide at these sites being 1.9 × 10 4 and 6.0 × 10 4 M -1 , respectively, for normal HSA. Two samples of glycated HSA had similar affinities to normal HSA for gliclazide at Sudlow site I, but one sample had a 1.9-fold increase in affinity at this site. All three glycated HSA samples differed from normal HSA in their affinity for gliclazide at Sudlow site II. This work illustrated how HPAC can be used to examine both the overall binding of a drug with normal or modified proteins and the site-specific changes that can occur in these interactions as a result of protein modification. [Figure not available: see fulltext.]

KW - Drug-protein interactions

KW - Gliclazide

KW - Glycation

KW - High-performance affinity chromatography

KW - Human serum albumin

UR - http://www.scopus.com/inward/record.url?scp=81855173602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855173602&partnerID=8YFLogxK

U2 - 10.1007/s00216-011-5382-8

DO - 10.1007/s00216-011-5382-8

M3 - Article

VL - 401

SP - 2811

EP - 2819

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 0016-1152

IS - 9

ER -